CS
AZN icon

Candriam SCA’s AstraZeneca AZN Stock Holding History

Candriam SCA’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-186,102
Closed -$26.6M – 663
2023
Q2 		$26.6M Sell
186,102
-117,924
-39% -$17.4M 0.19% 132
2023
Q1 		$38.8M Buy
304,026
+4,754
+2% +$640K 0.27% 90
2022
Q4 		$40.6M Sell
299,272
-5,742
-2% -$720K 0.27% 86
2022
Q3 		$33.5M Sell
305,014
-17,052
-5% -$2.16M 0.24% 98
2022
Q2 		$42.6M Sell
322,066
-116,864
-27% -$15.3M 0.35% 68
2022
Q1 		$58.2M Sell
438,930
-91,675
-17% -$11M 0.4% 61
2021
Q4 		$61.8M Buy
530,605
+16,388
+3% +$1.93M 0.39% 58
2021
Q3 		$61.8M Buy
514,217
+385,524
+300% +$44.9M 0.42% 54
2021
Q2 		$15.4M Buy
128,693
+46,901
+57% +$5.15M 0.11% 225
2021
Q1 		$7.86M Buy
81,792
+58
+0.1% +$5.83K 0.07% 294
2020
Q4 		$8.17M Buy
81,734
+22,181
+37% +$2.35M 0.06% 302
2020
Q3 		$6.53M Buy
59,553
+32,210
+118% +$3.58M 0.06% 312
2020
Q2 		$2.89M Sell
27,343
-22,697
-45% -$2.34M 0.03% 428
2020
Q1 		$4.88M Buy
50,040
+32
+0.1% +$3.01K 0.05% 353
2019
Q4 		$4.99M Buy
+50,008
New +$4.71M 0.05% 360
2018
Q1 		– Sell
-10,600
Closed -$736K – 765
2017
Q4 		$736K Sell
10,600
-6,838
-39% -$461K 0.01% 629
2017
Q3 		$1.18M Sell
17,438
-402
-2% -$25.4K 0.02% 544
2017
Q2 		$1.22M Hold
17,840
– – 0.02% 547
2017
Q1 		$1.11M Hold
17,840
– – 0.02% 548
2016
Q4 		$975K Hold
17,840
– – 0.02% 520
2016
Q3 		$1.17M Sell
17,840
-2,160
-11% -$141K 0.03% 465
2016
Q2 		$1.21M Buy
+20,000
New +$1.16M 0.03% 398

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Candriam SCA's AZN Position: Q3 2023 in Review

Candriam SCA sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 186,102 shares — an estimated $26.6M sold.

Candriam SCA first reported a position in AZN in Q2 2016 and held it in 22 quarters. The position peaked at $61.8M in Q4 2021. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Candriam SCA reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
  • Candriam SCA sold 186,102 AstraZeneca shares in Q3 2023, an estimated $26.6M.
  • Candriam SCA first reported a position in AstraZeneca in Q2 2016 and held it in 22 quarters.
  • Candriam SCA's AstraZeneca position peaked at $61.8M in Q4 2021.
  • 1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.